| [1] |
Jordan N, D'Cruz D. Current and emerging treatment options in the management of lupus[J]. Immunotargets Ther, 2016 (5): 9-20.
|
| [2] |
周丽，忻霞菲，吴华香.小剂量利妥昔单抗治疗原发性干燥综合征继发血小板减少四例疗效观察[J].中华内科杂志，2012，51（1）：37-41.
|
| [3] |
张之南.血液病诊断及疗效标准[M]. 2版.北京：科学出版社，1998：279.
|
| [4] |
Provan D, Butler T, Evangelista ML, et al. Activity a-nd safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults[J]. Haematologica, 2007, 92 (12): 1695-1698.
|
| [5] |
Chen H, Zheng W, Su J, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus-a prospective pilot study[J]. Rheumatology (Oxford), 2011, 50 (9): 1640-1644.
|
| [6] |
Lan L, Han F, Chen JH. Efficacy and safety of ritu-ximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis[J]. J Zhejiang Univ Sci B, 2012, 13 (9): 731-744.
|
| [7] |
Cobo-Ibanez T, Loza-Santamaria E, Pego-Reigosa JM, et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review[J]. Semin Arthritis Rheum, 2014, 44 (2): 175-185.
|
| [8] |
Zaja F, Vianelli N, Volpetti S, et al. Low-dose rituxi-mab in adult patients with primary immune thrombocytopenia[J]. Eur J Haematol, 2010, 85 (4): 329-334.
|
| [9] |
Hennigan S, Channick RN, Silverman GJ. Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report[J]. Lupus, 2008, 17 (8): 754-756.
|
| [10] |
王为，王迁，赵久良，等.利妥昔单抗治疗系统性红斑狼疮相关肺动脉高压的前景[J].基础医学与临床，2010，30（3）：317-319.
|
| [11] |
Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system[J]. Ann Rheum Dis, 2007, 66 (4): 470-475.
|
| [12] |
Narvaez J, Rios-Rodriguez V, de la Fuente D, et al. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence[J]. Semin Arthritis Rheum, 2011, 41 (3): 364-372.
|
| [13] |
Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease[J]. Neurology, 2014, 83 (2): 142-150.
|
| [14] |
Magro-Checa C, Zirkzee EJ, Huizinga TW, et al. Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives[J]. Drugs, 2016, 76 (4): 459-483.
|
| [15] |
Tanaka Y, Takeuchi T, Miyasaka N, et al. Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy[J]. Mod Rheumatol, 2015, 26 (1): 80-86.
|
| [16] |
Ezeonyeji AN, Isenberg DA. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen[J]. Rheumatology (Oxford), 2012, 51 (3): 476-481.
|
| [17] |
Smith KG, Jones RB, Burns SM, et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and retreatment[J]. Arthritis Rheum, 2006, 54 (9): 2970-2982.
|